http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A new cascaded multilevel converter topology with energy exchange unit for STATCOM application
Rongfeng Yang,Yinglin Zhang,Binbin Li,Rong xu,Yong yu,Dianguo Xu 전력전자학회 2015 ICPE(ISPE)논문집 Vol.2015 No.6
The star-connected H-bridge cascaded converter has the disadvantage of capacitors unbalance especially when the unbalance occurs between phases. This paper analyzed one novel topology with energy exchange unit (EEU) to realize the phase capacitors voltage balance. After analyzing the converter structure and balance operation concept, this paper provided detailed modulation and capacitors balance control, including maintaining the EEU capacitor voltage stable, sharing the energy storage between phases and in same phase. The simulation results demonstrate the correction of the topology and control.
Origin of Improved Photoelectrochemical Water Splitting in Mixed Perovskite Oxides
Li, Weiwei,Jiang, Kai,Li, Zhongguo,Gong, Shijing,Hoye, Robert L. Z.,Hu, Zhigao,Song, Yinglin,Tian, Chuanmu,Kim, Jongkyoung,Zhang, Kelvin H. L.,Cho, Seungho,MacManus-Driscoll, Judith L. Wiley (John WileySons) 2018 ADVANCED ENERGY MATERIALS Vol.8 No.31
Ying Lin,Mingxi Lin,Jian Zhang,Biyun Wang,Zhonghua Tao,Yiqun Du,Sheng Zhang,Jun Cao,Leiping Wang,Xichun Hu 대한암학회 2020 Cancer Research and Treatment Vol.52 No.4
Purpose Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. Materials and Methods One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included. Results Over half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea. Conclusion Pyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.